Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTLFree Report) in a report released on Monday morning, Benzinga reports. Needham & Company LLC currently has a $9.00 price objective on the stock.

Separately, Truist Financial raised their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a buy rating in a report on Tuesday, April 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $8.70.

Read Our Latest Analysis on Autolus Therapeutics

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $4.28 on Monday. The firm has a 50 day simple moving average of $4.51 and a 200-day simple moving average of $5.36. The stock has a market capitalization of $1.14 billion, a PE ratio of -3.57 and a beta of 2.02. Autolus Therapeutics has a 12-month low of $2.01 and a 12-month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTLGet Free Report) last posted its quarterly earnings data on Friday, May 17th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The firm had revenue of $10.09 million for the quarter, compared to analyst estimates of $50.00 million. During the same period in the previous year, the business earned ($0.23) EPS. On average, analysts forecast that Autolus Therapeutics will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Large investors have recently added to or reduced their stakes in the business. Schonfeld Strategic Advisors LLC bought a new stake in Autolus Therapeutics during the third quarter worth approximately $679,000. China Universal Asset Management Co. Ltd. acquired a new position in Autolus Therapeutics in the 4th quarter worth approximately $105,000. Exchange Traded Concepts LLC boosted its stake in Autolus Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 48,849 shares of the company’s stock worth $315,000 after purchasing an additional 12,387 shares during the period. Victory Capital Management Inc. acquired a new position in Autolus Therapeutics in the 4th quarter worth approximately $768,000. Finally, Lynx1 Capital Management LP acquired a new position in Autolus Therapeutics in the 3rd quarter worth approximately $3,176,000. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Further Reading

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.